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Objective: To determine the strength of evidence of preoperative statin therapy for prevention of atrial fibrillation
after cardiac surgery.
Methods: A meta-analysis was performed of randomized controlled trials and observational trials reporting the
impact of preoperative statin therapy on the incidence of any type and new-onset atrial fibrillation after cardiac
surgery. Unadjusted and adjusted treatment effects (odds ratio, 95% confidence intervals) were pooled using
a random-effects model, and publication bias was assessed.
Results: Thirteen studies were identified (3 randomized controlled trials, 10 observational trials) that reported the
incidence of postoperative atrial fibrillation in 17,643 patients having cardiac surgery with (n¼ 10,304; 58%) or
without (n¼ 7339; 42%) preoperative statin use. New-onset atrial fibrillation was reported in a total of 7855 pa-
tients. Postoperative incidence rates for any or new-onset atrial fibrillation were 24.6% and 29.9%, respectively.
Preoperative statin use resulted in a 22% and 34% unadjusted odds reduction for any atrial fibrillation (odds ratio,
0.78; 95% confidence interval, 0.67–0.90) or new-onset atrial fibrillation (odds ratio, 0.66; 95% confidence in-
terval, 0.51–0.84) after surgery (P<.001). Relevant publication bias and an unequal distribution of confounding
variables favoring patients treated with statins were identified. Nevertheless, the beneficial actions of statins on
atrial fibrillation persisted after pooled analysis of risk-adjusted treatment effects from randomized controlled tri-
als and observational trials (any atrial fibrillation—odds ratio, 0.64; 95% confidence interval, 0.48–0.87; new-
onset atrial fibrillation—odds ratio, 0.66; 95% confidence intervals, 0.48–0.89; P< .01).
Conclusion: Our meta-analysis provides evidence that preoperative statin therapy is associated with a reduction
in the incidence of atrial fibrillation after cardiac surgery.Supplemental material is available online.
Atrial fibrillation (AF) is a common complication after car-
diac surgery and is associated with increased morbidity and
prolonged hospitalization with significant economic impli-
cations.1,2 Although perioperative predictors of AF are iden-
tified and various preventive pharmacologic and surgical
strategies have been introduced,3,4 the incidence of AF after
cardiac surgery remains high, occurring in 20% to 40% of
patients.1,2 Beyond the involvement of a multitude of perio-
perative factors including alterations in the autonomic and
metabolic response and oxidative myocardial stress, inflam-
mation has been suggested recently to play a pivotal role in
the pathogenesis of AF after cardiac surgery.5,6
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tase inhibitors) exert multiple pleiotropic actions indepen-
dently of their lipid-lowering properties. We and others
have demonstrated that preoperative statin therapy decreases
markers of inflammation7,8 and attenuates myocardial reper-
fusion injury after cardiac surgery.9 Thus, use of statins prior
to heart surgery may contribute to improved perioperative
cardiac protection with a favorable impact on the incidence
of AF. Consistent with this, the ARMYDA-3 trial demon-
strated a 61% reduction in the odds for new-onset AF in
patients randomly allocated to 7-day atorvastatin treatment
before elective heart surgery.6 However, conclusions drawn
from this study were limited by the relatively small sample
size (n ¼ 200) and unusually high incidence rates of AF re-
ported in the placebo group (57%). Moreover, evidence
from previous reviews investigating the potential benefits
of statins on postoperative AF in cardiac surgery is inconclu-
sive,10-12 as controversial data from recent reports with more
patients have become available.13-17 Limited clarity of avail-
able data underscores the need for an updated comprehen-
sive review of this potentially relevant therapeutic strategy.
The primary objective of the present meta-analysis was to
determine the strength of evidence for preoperative statin
therapy for prevention of AF after cardiac surgery, with spe-
cial focus on new-onset AF. As a secondary objective, we
sought to identify possible confounding factors that may
limit the observed treatment effects of statins on AF.gery c September 2009
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MAbbreviations and Acronyms
ACE ¼ angiotensin-converting enzyme
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
OR ¼ odds ratio
RCT ¼ randomized controlled trial
METHODS
Selection Criteria and Search Strategy
A systematic review of the literature was performed following the guide-
lines for quality of reporting of meta-analysis.18,19 Randomized controlled
trials (RCTs) and observational studies published between 1966 and July
2008 that reported the effects of preoperative statin therapy on the incidence
of postoperative AF in adult patients having cardiac surgery were identified
and analyzed using a priori defined inclusion criteria: (1) studies reporting
the use of any commercially available statin before cardiac surgery for
any given duration and dose, and (2) studies comparing patients with or
without preoperative statin therapy. Postoperative AF was defined as occur-
rence of any type of postoperative AF. New-onset AF was recorded when
studies indicated exclusion of patients with a history of preoperative AF
from their studies, including permanent (chronic), persistent, or paroxysmal
AF. We disregarded atrial flutter or supraventricular tachycardia and ac-
cepted the authors’ postoperative monitoring modalities and definitions
for AF.
An electronic literature search was performed by two investigators
(O.J.L. and M.B.) in Medline, EMBASE, and The Cochrane Library using
a predefined keywords list (See Supplemental data S1—search strategy). All
studies published in full-text or abstract forms were eligible for inclusion
without applying any language restrictions. In addition, abstracts and oral
presentations from the past 3 years’ scientific meetings of the American
Heart Association, American College of Cardiology, European Society of
Cardiology, American Association of Thoracic Surgery, Society of Tho-
racic Surgeons, European Association of Cardiothoracic Surgery, and Soci-
ety of Cardiovascular Anesthesiology were screened. Studies not including
a control group, animal studies, in vitro studies, prevention trials, editorials,
letters, review articles, or trials that exclusively reported other clinical out-
comes were excluded after initial abstract review. All potentially relevant
studies were identified and full-text publications retrieved for detailed eval-
uation. References of relevant reports and reviews were screened to identify
other eligible studies. When more than 1 publication from the same patient
cohort existed, then the study with the most complete data set was included
in the systematic review.
Data Extraction and Quality Assessment
All data with regard to authorship, year of publication, type of publica-
tion (abstract, full-text), study design, patient population (sample size, age,
preoperative risk factors, type of surgery), length of preoperative statin ex-
posure, applied statin regimen, length of follow-up, preoperative medica-
tions (antiarrhythmic medication), and type of AF (any AF vs new-onset
AF) were extracted. Methodologic quality of the included studies was as-
sessed by two independent investigators (O.J.L. and Y.-H.C.) using the Ja-
dad Score (total score from 0 [poor] to 5 [excellent]) for RCTs20 and the
Downs and Black Checklist (total score from 0 [poor] to 29 [excellent])
for both RCTs and observational trials, respectively.21 Disagreements
were resolved by consensus.
Statistics
Statistical analyses were performed using Review Manager (Version
5.0.1.4; The Nordic Cochrane Centre, Købehavn, Denmark) and StatsDirectThe Journal of Thoracic and Cstatistical software package, version 2.6.8 (StatsDirect Ltd., Chelsire, UK).
For each individual study, the raw incidence data were used to calculate the
unadjusted ‘‘crude’’ odds ratio (OR). Adjusted OR resulting from multivar-
iate analysis or propensity score matching of treatment groups were ex-
tracted from included studies. To control for confounding covariates, an
estimated summary OR was generated by combining all studies reporting
adjusted and unadjusted OR (combined OR) and summarized by Forest
plots. Furthermore, an overall adjusted OR was calculated after considering
only RCTs and observational trials reporting adjusted treatment effects. Q-
statistics and I2-statistics were performed to test for heterogeneity between
included studies.22 In the presence of heterogeneity (Q-statistics P< .10 or
I2> 50%), the DerSimonian and Laird random-effects model was used.
Pooled treatment effect estimate was calculated as a weighted average of
the treatment effects so that an OR of less than 1 favored statin treatment
over control. For continuous variables, the weighted mean difference was
calculated. In 1 case, missing information on the type of AF was retrieved
by contacting the primary author of the study.23 A meta-regression analysis
of summary statistics was conducted to investigate the impact of perioper-
ative covariates of study characteristics on the statin effect estimates (loga-
rithmic OR) on AF, includingmean age of patients and percentage of female
patients, nonelective type of surgery, hypertension, diabetes and preopera-
tive use of ß-blocker, angiotensin-converting enzyme (ACE) inhibitor, or
antiplatelet therapy (ie, aspirin).
A funnel plot was constructed to visually assess the presence of publica-
tion bias. The treatment effects, given as the OR on a logarithmic scale, were
plotted against a measure of precision expressed as the standard error. Ad-
ditionally, publication bias was assessed by applying the Egger’s weighted
regression statistic. Sensitivity analysis was performed to estimate differ-
ences of treatment effects between prospective and retrospective trials and
to account for low- and high-quality studies (Downs and Black score 21
or>21, respectively).
RESULTS
Selection and Characteristics of Included Studies
A search of the literature retrieved 1142 studies of which
1106 (96.9%) were excluded after initial abstract review for
reasons explained in Figure 1. Of the remaining 36 studies,
23 studies were excluded after full-text evaluation either due
to insufficient reporting of desired clinical end points (n ¼
21) or due to inclusion of the same patient population in
more than 1 publication (n ¼ 2). (See supplemental data
S2—references.)
After critical appraisal, 13 unique full-text studies pub-
lished between the years 2004 to July 2008 fulfilled our in-
clusion criteria, reporting the influence of preoperative statin
therapy on the incidence of postoperative AF in a total of
17,643 patients having heart surgery. Three studies were
RCTs,6,7,17 and 2 studies used a prospective observa-
tional15,24 and 8 a retrospective design.13,14,16,23,25-28 One
study examined the effects of preoperative lipid-lowering
therapy rather than statin therapy on postoperative out-
comes.27 Because the vast majority of these patients re-
ceived statins (86%) compared with other lipid-lowering
agents (14%) before surgery, this report was included in
our systematic review.Moreover, a recently published, nested
patient cohort analysis from the Atrial Fibrillation Suppres-
sion Trials I, II and III (AFIST) was also included, despite ap-
proximately 45% of enrolled patients being randomized to
a prophylactic oral amiodarone therapy before surgery.14ardiovascular Surgery c Volume 138, Number 3 679
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screened databases
n = 1142
Abstracts excluded after review  (n=1106)
• nonrelated topic (n=967)
• other outcomes, case reports (n=29)
• animal, in vitro studies (n=14)
• prevention trials (n=44)
• comments, editorial, letter (n=23)
• review article (n=29)
Relevant studies retrieved for
detailed evaluation
n = 36
Excluded after full-text review
• outcomes not reported (n=21)
• patients included in previous study (n=2) 
Studies included in the
meta-analysis
n = 13  
(n=23)
FIGURE 1. Flow diagram of the systematic literature search.Table 1 summarizes the characteristics of the included
studies. Of 17,643 patients, 10,304 (58.4%) patients were
on preoperative statin therapy compared with 7339
(41.6%) patients without statins. Eight studies focused on
isolated coronary artery bypass grafting (CABG; 90.7%;
16,008 patients), and 5 studies included patients having iso-
lated valve surgery (6.5%; 1147 patients) or both (2.8%;
488 patients). Elective surgery was performed in 83.5%
(14,740 patients) of patients, and all operations were primary
procedures with predominant use of CPB (97.7%; 17,002
patients). Various statin types, dosage, and reinitiation regi-
mens were used. Preoperative statin exposure ranged from
the day of hospital admission to over 2 months preopera-
tively, and follow-up periods for postoperative AF ranged
until the day of discharge to 30 days after surgery.
Quality of Included Studies
The Jadad quality score was 5 (excellent) or 3 (good) for
the 3 RCTs, respectively (Table 1). An average Downs and
Black score of 21.9  2.6 was achieved for all 13 studies
(range 18–28 points). Only 4 studies were rated of being
of low quality and scored below 21 points. Lack of random-
ization and blinding in the 10 observational trials were indi-
cated by low scores for internal validity bias and
confounding that averaged 5.1  1.0 and 3.8  1.0, respec-
tively. Study quality ratings correlated significantly (P<
.0001) between the 2 independent investigators with a Spear-
man correlation coefficient of 0.93.
Analyzed Outcomes
Analysis of pooled prevalence of preoperative patient
group characteristics revealed that patients receiving preop-680 The Journal of Thoracic and Cardiovascular Sueratively statins were more likely to be younger and male, to
have diabetes, hypertension, or hyperlipemia, and to receive
a ß-blocker, ACE inhibitor, or aspirin therapy before surgery
(Table 2). In contrast, more patients without statins had non-
elective surgery, although no differences were observed for
history of myocardial infarction, calcium channel blocker
therapy, off-pump procedures, or cardiopulmonary bypass
and aortic crossclamp time.
Any AF type. AF incidence after cardiac surgery was
24.6% for the entire patient population (4335 of 17,643
patients) and was significantly lower in patients receiving
preoperative statin therapy compared with controls (22.3%
vs 27.8%, P<.0001). Statin use resulted in a 5.5% absolute
(number needed to treat: 18.2) and 19.9% relative risk
reduction for postoperative AF. Significant heterogeneity
(P ¼ .0010; I2 ¼ 63%) between studies was accounted for
by employing a random-effects model. Statin use was asso-
ciated with a 22% reduction in the unadjusted odds for any
type of AF (P¼ .0010 for overall effect; Table 3). A similar
reduction in the odds for AF was observed in statin-pre-
treated patients after combining all studies reporting ad-
justed and unadjusted ORs (P ¼ .0025 for overall effect;
Table 3). Importantly, inclusion of only adjusted treatment
effects from RCT6,7,17 and observational trials13-16,24,25
into the summary analysis revealed a 36% reduction in the
odds for developing any type of postoperative AF in sta-
tin-treated patients (P ¼ .0044 for overall effect; Figure 2).
However, the latter analysis included predominantly trials
that reported incidences of new-onset AF with the exception
of 1 study.7
New-onset AF. Subgroup analysis for new-onset AF dem-
onstrated a 29.9% postoperative incidence rate in 9 analyzedrgery c September 2009
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statin use resulted in a significantly lower incidence of
new-onset AF after cardiac surgery when compared with
control (28.2% vs 32.2%; P¼ .0001) with a 4.0% absolute
(number needed to treat: 25.1) and 12.4% relative risk re-
duction for new-onset AF. Statistical heterogeneity was
present between included studies (P ¼ .0002; I2 ¼ 73%).
Statin pretreatment was associated with a 34% unadjusted
odds reduction for developing new-onset AF after surgery
(P ¼ .0008 for overall effect; Table 3). Moreover, the esti-
mated statin effect on new-onset AF persisted even after
combining adjusted and unadjusted ORs from included stud-
ies (P ¼ .0025 for overall effect; Table 3) or after summary
meta-analysis from included RCTs and observational stud-
ies that controlled for covariates (P ¼ .0070 for overall ef-
fect; Figure 2).6,13-17,24,25
Meta-Regression, Sensitivity Analysis,
and Publication Bias
Meta-regression analysis revealed that percentage use of
ß-blocker (P ¼ .0437) and ACE inhibitors (P ¼ .0276)
were the only covariates statistically significantly associated
with improved statin treatment estimates for new-onset AF,
but not for any AF (P> .05), and might therefore explain
heterogeneity among study results. Sensitivity analysis of
studies rated as being of low-quality rating (P ¼ .2629 for
overall effect; Figure 2) failed to reveal a significant reduc-
tion in the combined odds for developing any type of AF in
statin-pretreated patients. In contrast, treatment effects that
favored preoperative statin use remained when only retro-
spective trials were analyzed and were even greater when
only prospective trials or studies rated as being of good qual-
ity were taken into consideration.
Significant publication bias was confirmed for both end
points (any AF, P¼ .0003; new-onset AF, P¼ .0001) using
Egger’s weighted regression analysis. Assessment of publi-
cation bias using visual examination of the funnel plot re-
vealed asymmetry around the mean OR with smaller
studies tending toward larger positive effects (Figure 3).
DISCUSSION
Our literature review suggests that preoperative use of sta-
tins significantly reduces the incidence of AF after cardiac
surgery. Analysis of 17,643 patients having cardiac surgery
demonstrated a 5.5% absolute risk reduction and 22% un-
adjusted odds reduction for the end point of any type of
AF in patients pretreated with statins, which persisted after
controlling for confounding variables by implementing
risk-adjusted treatment effects of included studies. Of note,
the odds reduction for any type of postoperative AF was
greater when considering only RCTs and risk-adjusted ob-
servational trials. In addition, subgroup analysis revealed
a similar treatment effect of statins for the development of
new-onset AF. The beneficial effects of statins on new-onsetThe Journal of Thoracic and CAF remained significant, independently of whether unad-
justed, combined, or fully-adjusted effect estimates of in-
cluded studies were summarized.
Several factors need to be taken into consideration for
valid interpretation of the observed statin benefits. Heteroge-
neity of included studies was evident and probably can be
ascribed to perioperative differences in the statin treatment
regimen, antiarrhythmic strategy, follow-up periods, and
AF detection modalities across included studies. In addition,
the observed statin effects are largely based on observational
datasets including 8 retrospective studies.13,14,16,23,25-28 On
the other hand, the statin-related reduction in the odds for de-
velopment of any AF were more prominent when consider-
ing only prospective trials or studies being rated of good
methodologic quality. These observations imply that the
true impact of a statin pretreatment on the incidence of AF
after cardiac surgery may be underestimated by our review.
Consistent with this, the only double-blinded RCTs allocat-
ing patients to prespecified statin doses (atorvastatin 20 to 40
mg/d) and treatment periods before cardiac surgery (3 to 21
days) demonstrated a 61% to 67% reduction in the odds for
postoperative AF.6,7,17 Nonetheless, evidence supporting
perioperative statin use for prevention of AF remains incon-
clusive because all randomized trials enrolled only a small
number of patients with limited control for perioperative
variables or blinding. Furthermore, the AF incidence rates
in the placebo arm of the ARMYDA-3 trial6 (statin group
35% vs placebo group 57%; P< 0.003) was higher than
the expected 20% to 40% AF rates after cardiac surgery
usually reported in the current literature1,2 and by our
meta-analysis (24.6%).
Importantly, in an attempt to control for potential selec-
tion and treatment bias, our meta-analysis identified an un-
equal distribution of possible confounding factors,
including a higher prevalence of younger patients with
more elective procedures and ß-blocker, ACE inhibitor, or
aspirin therapy in the statin-pretreated group when com-
pared with controls (P < 0.01). Mathew et al1 reported
a 75% increase in the odds of developing AF after cardiac
surgery for every 10-year increase in age, thereby indicating
the relevance of age-associated structural changes in the
atrium for AF.4 Similarly, ß-blocker or ACE inhibitor treat-
ment prior to cardiac surgery has been repeatedly reported to
be independently associated with reduced AF incidence
rates after cardiac surgery.1,4,29,30 Conversely, neither the
status of surgery (ie, elective vs nonelective surgery) nor
the use of antiplatelet agents has been identified as being
of predictive value for the development postoperative
AF.1,2 Nevertheless, the observed treatment bias parallels
the findings shown in a recent literature review11 and indi-
cates a more aggressive periprocedural risk management
with superior cardioprotection in patients receiving statins.
Although our results accounted for confounding bias by gen-
erating pooled treatment effects from observational studiesardiovascular Surgery c Volume 138, Number 3 681
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Study Design
Study
population
Size
(age)
Statin/
no statin
Exposure
(d)
Statin type;
dose; reinitiation Afib type
Follow-up
(d) QoS*
Pan (2004)26 R Isolated CABG
with CPB
1663 (63) 943/720 —y Atorvastatin,
simvastatin,
lovastatin,
pravastatin,
fluvastatin,
cerivastatin;
NR; NR
Any AF n/a —/19
Chello (2006)7 RCT Isolated CABG
with CPB
40 (65) 20/20 21 Atorvastatin; 20
mg/d; NR
Any AF To discharge
(7 d)
3/24
Marin (2006)24 PO Isolated CABG;
off-pump 39%
234 (65) 144/90 31 NR; NR; NR New-onset AF 30 —/18
Patti (2006)6 RCT Elective CABG
79% and valve
surgery 21%;
with CPB
200 (66) 101/99 7 Atorvastatin; 40
mg/d; given
until discharge
New-onset AF To discharge
(7 d)
5/28
Mariscalco
(2007)25
R Isolated CABG;
off-pump 21%
405 (66) 218/187 46 38% atorvastatin,
44%
simvastatin,
18% other;
mean dose 22
mg/d; NR
New-onset AF To discharge
(8 d)
—/22
Ozaydin
(2007)28
R Primary CABG
98% and valve
surgery 2%;
off-pump 5%
362 (61) 267/95 >60 44% atorvastatin,
26%
simvastatin,
20%
fluvastatin,
10%
pravastatin;
mean dose 27
mg/d; given
after surgery
New-onset AF 7 —/19
Powell
(2007)27
R Isolated CABG
with CPB
4739 (67) 2334/2405 <30 86% statins (14%
other) NR; NR
Any AF To discharge —/23
Thielmann
(2007)23
R Isolated CABG
with CPB
3346 (66) 2592/754 —y Atorvastatin,
simvastatin,
lovastatin,
pravastatin,
fluvastatin,
cerivastatin;
NR; NR
Any AF To discharge
(8–9 d)
—/23
Lertsburapa
(2008)14
R Nested, cohort
from AFIST I-
III trial; CABG
or valve surgery
85%, isolated
valve surgery
15%; off-pump
33%
555 (67) 331/224 —y Atovastatin-,
simvastatin,
lovastatin,
pravastatin,
fluvastatin,
cerivastatin,
rosuvastatin;
NR;
reinitiation;
rate: 87%
New-onset AF 30 —/23
Subramaniam
(2008)15
PO Isolated CABG
with CPB
1308 (66) 654/654 —y NR; NR; NR New-onset AF To discharge
(6 d)
—/22682 The Journal of Thoracic and Cardiovascular Surgery c September 2009
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Study Design
Study
population
Size
(age)
Statin/
no statin
Exposure
(d)
Statin type;
dose; reinitiation Afib type
Follow-up
(d) QoS*
Kourliouros
(2008)13
R CABG 78%,
aortic valve
surgery 12%,
or both 10%;
with CPB
623 (67) 542/81 >60 39% atorvastatin
or 56%
simvastatin,
other statins
5%; 10–80 mg;
NR
New-onset AF To discharge —/22
Virani
(2008)16
R Primary CABG
66%, valve
surgery 25%,
or both 9%;
with CPB
4044
(48%>65)
2096/1948 —y Atorvastatin,
simvastatin,
lovastatin,
pravastatin,
fluvastatin,
cerivastatin,
rosuvastatin;
NR; NR
New-onset AF To discharge —/20
Song (2008)17 RTz Isolated off-pump
CABG
124 (63) 62/62 3 Atorvastatin; 20
mg/d; given
until discharge
New-onset AF To discharge
(7 d)
3/24
Key characteristics of included studies including design, type of surgery, sample size, and mean age of patient groups; preoperative statin exposure (mean days); statin therapy
regimen; and measured outcomes during the postoperative follow-up period (mean days). AF, Atrial fibrillation; CABG, coronary artery bypass grafting; CPB, cardiopulmonary
bypass;NR, not reported; PO, prospective observational;QoS, quality of study; R, retrospective; RCT, randomized controlled trial. *Quality assessment of included studies with the
Jadad (only for RCT; total score from 0 [poor] to 5 [excellent]) and the Downs and Black score (total score from 0 [poor] to 29 [excellent]). yTaking statins preoperatively. zNot
placebo-controlled or blinded.P
Mwith statistical adjustments for covariates,13-16,24,25 it must
be noted that variables adjusted for differed among trials.
Furthermore, meta-regression analysis indicated that preop-
erative ß-blocker and ACE inhibitor therapy may serve as
potential covariates associated with improved statin treat-
ment effects for new-onset AF, a finding that is, however,
limited by its low methodologic quality and power. There-
fore, even after meta-analysis, it remains unclear whether
or not the reported benefits of a preoperative statin therapyThe Journal of Thoracic and Con postoperative AF is just a surrogate marker for con-
founders that independently prevent the development of
AF after cardiac surgery.
The importance of a potentially preventive strategy for AF
with statins is underscored by reports showing a significant in-
crease in early morbidity in patients have cardiac surgery with
postoperative AF, including an approximately threefold
higher risk for stroke and longer need for ventilatory and ino-
tropic support.1,2,31 Moreover, postoperative AF is known toTABLE 2. Perioperative variables of patients
Dichotomous Sample size (n) Prevalence% (n) Treatment groups,% (n) c2 test (P value)
Female gender 17,409 25.0% (4359) Statin 24.2% (2460); control 26.2% (1899) .0029
MI history 17,369 40.1% (6966) Statin 40.7% (4122); control 39.3% (2844) .0826
Diabetes 17,409 23.3% (4056) Statin 24.9% (2532); control 21.0% (1524) <.0001
Hyperlipemia 14,521 70.8% (10288) Statin 91.3% (7620); control 43.2% (2668) <.0001
Hypertension 12,670 77.3% (9798) Statin 80.7% (6313); control 71.9% (3485) <.0001
ACE inhibitors 15,706 46.2% (7259) Statin 52.7% (4846); control 37.1% (2413) <.0001
ß-blocker 17,409 66.1% (11513) Statin 71.6% (7278); control 58.4% (4235) <.0001
CCB 6686 32.7% (2185) Statin 32.8% (1185); control 32.5% (1000) .7577
Aspirin 15,462 69.9% (10811) Statin 73.6% (6541); control 64.9% (4270) <.0001
Nonelective surgery 17,643 16.5% (2903) Statin 15.8% (1628); control 17.4% (1275) .0055
Off-pump surgery 17,409 2.3% (407) Statin 2.4% (247); control 2.2% (160) .3352
Continuous Sample size (N) WMD 95% CI Overall effect (P value)
Age (y) 13,365 1.00 1.86–0.13 .0247
CPB time (min) 10,683 0.05 2.84–2.75 .9748
AoX time (min) 10,060 1.22 4.09–1.64 .4023
Comparison of the pooled dichotomous and continuous preoperative variables (WMD; [] favors statins) in patients pretreated with statins or controls. ACE, Angiotensin-convert-
ing enzyme inhibitors; AoX, aortic crossclamp time; CCB, calcium channel blockers; CI, confidence interval; CPB, cardiopulmonary bypass; MI, myocardial infarction; WMD,
weighted mean difference.ardiovascular Surgery c Volume 138, Number 3 683
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Events (Total)
Study ID Statins Control
Unadjusted OR
(95% CI) Adjusted SE Combined OR (95% CI)
Pan 200426 176 (943) 135 (720) 0.99 (0.78–1.28) n/a 0.13 0.99 (0.78–1.28)
Chello 20067 2 (20) 5 (20) 0.33 (0.06–1.97) n/a 0.89 0.33 (0.06–1.97)
Marin 200624 33 (144) 33 (90) 0.51 (0.29–0.92) MVA 0.31 0.52 (0.28–0.96)
Patti 20066 35 (101) 56 (99) 0.41 (0.23–0.72) MVA 0.4 0.39 (0.18–0.85)
Mariscalco 200725 64 (218) 77 (187) 0.59 (0.39–0.90) PS 0.23 0.58 (0.37–0.91)
Ozaydin 200728 22 (267) 16 (95) 0.44 (0.22–0.89) n/a* 0.36 0.44 (0.22–0.89)
Powell 200727 672 (2334) 734 (2405) 0.92 (0.81–1.04) n/a 0.06 0.92 (0.81–1.04)
Thielmann 200723 201 (2592) 61 (754) 0.96 (0.71–1.29) n/a 0.15 0.96 (0.71–1.29)
Lertsburapa 200814 92 (331) 82 (224) 0.67 (0.46–0.96) MVA 0.25 0.60 (0.37–0.99)
Kourliouros 200813 147 (542) 31 (81) 0.60 (0.37–0.98) PS 0.25 0.50 (0.31–0.81)
Subramaniam 200815 184 (654) 182 (654) 1.02 (0.80–1.29) PS 0.12 1.02 (0.80–1.29)
Virani 200816 658 (2096) 612 (1948) 1.00 (0.87–1.14) MVA, PS 0.11 1.14 (0.92–1.41)
Song 200817 8 (62) 17 (62) 0.39 (0.15–0.99) MVA 0.52 0.34 (0.12–0.93)
Summary
Any AF 2294 (10304) 2041 (7339) 0.78 (0.67–0.90)y 0.76 (0.64–0.91)z
New-onset AF 1243 (4415) 1106 (3440) 0.66 (0.51–0.84)x 0.63 (0.47–0.85)k
Summary of meta-analysis for the end point any type of atrial fibrillation or new-onset AF (in bold). Pooled treatment effect estimate was calculated as a weighted average of the
unadjusted or combined OR (unadjusted and adjusted OR) from included studies. Methods of controlling for confounding factors are indicated (MVA or PS). AF,Atrial fibrillation;
CI, confidence interval; MA, multivariate analysis; OR, odds ratio; PS, propensity score matching; SE, standard error; n/a, not applicable. *Reported risk reduction but no ORs.
yHeterogeneity: Cochran Q ¼ 32.69 (df¼ 12), P¼ .0010; I2¼ 63%; random-effects (DerSimonian-Laird): z¼ 3.30, P ¼ 0.0010. zHeterogeneity: Cochran Q ¼ 34.91 (df¼ 12),
P ¼ .0005; I2 ¼ 66%; random-effects (DerSimonian-Laird): z ¼3.02, P ¼ .0025. xHeterogeneity: Cochran Q ¼ 29.69 (df ¼ 8), P ¼ .0002; I2 ¼ 73%; random-effects (DerSi-
monian-Laird): z ¼ 3.34, P ¼ .0008. kHeterogeneity: Cochran Q ¼ 31.65 (df ¼ 8), P ¼ .0001; I2 ¼ 75%; random-effects (DerSimonian-Laird): z ¼3.03, P ¼ .0025.prolong hospitalization periods with significant impact on the
costs of care.32Despite these substantial clinical and economic
implications, it is important to emphasize that the results of the
present meta-analysismust not be taken as an endorsement for
a preemptive statin use in all cardiac surgery patients for sev-
eral reasons. First, the observed treatment estimate of statins
was derived from a pooled patient cohort having predomi-
nantly CABG (91%) and, therefore, cannot be extrapolated
to patients scheduled for valve surgery. In agreementwith this,
no beneficial statin effect on postoperative AF could be found
for patients having surgery for valvular heart disease in RCT684 The Journal of Thoracic and Cardiovascular Suand retrospective studies.6,16 Second, the scarcity of controlled
trials resulted in a high variability of statin agents used, doses,
and treatment durations, making the identification of the most
effective statin therapy regimen impossible. In fact, a dose-de-
pendent statin-related reduction of postoperativeAFoccurring
at intermediate to high simvastatin or atorvastatin doses was
recently reported by 2 observational studies.13,14 The effec-
tiveness of high-dose atorvastatin therapy is also reflected in
the results of the ARMYDA-3 trial6 but not supported by an
analysis of 2 nonsurgical RCTs that failed to find a difference
in the incidence of AF when comparing standard-dose versusfavors statins favors control OR (95% CI) P value
.0010
.0025
.0044
.0008
.0025
.0070
.0353
.0314
.0033
.2629
0.2 0.5 1 2
Downs and Black score <= 21
Downs and Black score > 21
Retrospective trials, only
Prospective trials, only
New-onset AF (adjusted OR)
New-onset AF (combined OR)
New-onset AF (unadjusted OR)
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Any AF (combined OR)
Any AF (unadjusted OR)
0.82 (0.57, 1.16)
0.72 (0.58, 0.90)
0.81 (0.67, 0.98)
0.55 (0.31, 0.96)
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0.63 (0.47, 0.85)
0.66 (0.51, 0.84)
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0.76 (0.64, 0.91)
0.78 (0.67, 0.90)
FIGURE 2. Subgroup and sensitivity analysis comparing pooled treatment estimates (odds ratios [OR] and 95% confidence intervals [CI]) of preoperative
statins on the incidence of any type or new-onset atrial fibrillation (AF) after cardiac surgery.rgery c September 2009
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Liakopoulos et al Perioperative Managementhigh-dose statin therapy in patients with acute coronary syn-
dromes.33-35 Although differing pathophysiologic mecha-
nisms for the development of AF might be primarily
responsible for the observed discrepancies between patients
having cardiac surgery and patients with acute coronary syn-
drome, the optimal statin treatment protocol for prevention
of postoperative AF remains to be established. Last, our
meta-analysis was unable to distinguish whether lipid-lower-
ing or pleiotropic actions were responsible for the observed
treatment effects and could not validate the importance of rig-
orous postoperative reinitiation protocol due to inconsistent re-
porting. However, both factors are of considerable interest for
appropriate selection of patients who might profit the most
from an intensified perioperative statin treatment, especially be-
cause recent trials have shown that postoperative statin with-
drawal is independently associated with increased in-hospital
mortality36 and that statins reduce the risk of major adverse car-
diac events only in hyperlipemic patients having CABG.23
This meta-analysis has some further limitations. Although
interpretation of the funnel plot may be restricted in the pres-
ence of heterogeneity, significant publication bias was identi-
fied indicating that smaller studies reporting positive treatment
effects were more likely to be published than trials with nega-
tive findings. Thus, themagnitude of the reported treatment ef-
fects may be overestimated, especially because larger studies
included in this analysis reported none or only a moderate sta-
tin treatment effect onAF.16,23,26,27 In addition, ourmeta-anal-
ysis is limited by the heterogeneity of themainly observational
datasets and the lack of availability of all relevant data. Never-
theless, these restrictions were addressed by following current
recommendations for reporting a meta-analysis with assess-
ment of study quality, sensitivity analysis to account for
possible differences in study quality, and employment of ran-
dom-effects models to calculate pooled estimates. In addition,
separate analysis of studies reporting unadjusted and adjusted
treatment effects confirmed the beneficial effects of a preoper-
-3 -2 -1 0 1 2
1.0
0.8
0.6
0.4
0.2
0.0
Log(Odds ratio)
Standard error
FIGURE 3. Funnel plot with open circles representing included studies in-
vestigating the impact of a preoperative statin use on the incidence of any
type of atrial fibrillation. Solid lines, 95% confidence interval.The Journal of Thoracic and Cative statin therapy on the development of AF, hence increas-
ing the confidence in the validity of our results.
In conclusion, the present meta-analysis demonstrates
a reduction in the incidence of AF for patients pretreated
with statins and having cardiac surgery. Although our re-
view involved over 17,000 patients, relevant publication
bias and heterogeneity of studies mandate future RCTs to
define the perioperative role of statins for prevention of
AF, especially for normolipemic patients and patients with
valvular heart disease. Conversely, we believe that it is in
compliance with current evidence and existing guidelines37
to advocate an intensified perioperative statin therapy in all
patients with hyperlipemia and multiple cardiac risk factors
who are scheduled for coronary artery surgery.
We thank Dr Jonathan Ho (Department of Anesthesiology, Di-
vision of Cardiothoracic Anesthesia, University of California Los
Angeles, Calif) for his editorial assistance.
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